Literature DB >> 12220330

Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets.

Maria Cecília Picinato1, Esther Piltcher Haber, José Cipolla-Neto, Rui Curi, Carla Roberta de Oliveira Carvalho, Angelo Rafael Carpinelli.   

Abstract

The effect of melatonin (0.1 microM) on freshly isolated islets from adult rats was investigated. Melatonin caused a marked decrease of insulin secretion by islets in response to glucose. The mechanism involved was then examined. Melatonin did not interfere with glucose metabolism as indicated by the measurement of glucose oxidation. However, the content of the protein kinase A (PKA) catalytic alpha-subunit was significantly decreased in islets exposed to melatonin for 1 hr in the presence of 8.3 mM glucose, whereas that of the protein kinase C (PKC) alpha-subunit remained unchanged. Melatonin also inhibited forskolin-induced insulin secretion, a well known activator of adenylate cyclase (AC) activity. This may explain the low content of insulin found in islets incubated in the presence of melatonin for 3 hr. In fact, 3',5' -cyclic adenosine monophosphate (cAMP), a product of AC activity, stimulates insulin synthesis. These findings led us to postulate that a down-regulation of the PKA signaling pathway may be the mechanism involved in the melatonin inhibition of the process of glucose-induced insulin secretion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220330     DOI: 10.1034/j.1600-079x.2002.02903.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  24 in total

1.  The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus).

Authors:  E Peschke; K Hofmann; I Bähr; S Streck; E Albrecht; D Wedekind; E Mühlbauer
Journal:  Diabetologia       Date:  2011-04-15       Impact factor: 10.122

Review 2.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

3.  Role of melatonin on diabetes-related metabolic disorders.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  World J Diabetes       Date:  2011-06-15

4.  Melatonin reduces intramuscular fat deposition by promoting lipolysis and increasing mitochondrial function.

Authors:  Kaiqing Liu; Wensai Yu; Wei Wei; Xinbao Zhang; Ye Tian; Melak Sherif; Xin Liu; Chao Dong; Wangjun Wu; Lifan Zhang; Jie Chen
Journal:  J Lipid Res       Date:  2018-12-14       Impact factor: 5.922

Review 5.  Regulation of insulin synthesis and secretion and pancreatic Beta-cell dysfunction in diabetes.

Authors:  Zhuo Fu; Elizabeth R Gilbert; Dongmin Liu
Journal:  Curr Diabetes Rev       Date:  2013-01-01

6.  Circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in rats.

Authors:  Irina A Vinogradova; Vladimir N Anisimov; Andrey V Bukalev; Anna V Semenchenko; Mark A Zabezhinski
Journal:  Aging (Albany NY)       Date:  2009-10-02       Impact factor: 5.682

Review 7.  Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene.

Authors:  H Mulder; C L F Nagorny; V Lyssenko; L Groop
Journal:  Diabetologia       Date:  2009-04-18       Impact factor: 10.122

Review 8.  Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Authors:  Bo Ahrén
Journal:  Nat Rev Drug Discov       Date:  2009-04-14       Impact factor: 84.694

Review 9.  Melatonin Effects on Glucose Metabolism: Time To Unlock the Controversy.

Authors:  Marta Garaulet; Jingyi Qian; Jose C Florez; Josephine Arendt; Richa Saxena; Frank A J L Scheer
Journal:  Trends Endocrinol Metab       Date:  2020-01-01       Impact factor: 12.015

Review 10.  Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon.

Authors:  Elmar Peschke; Ina Bähr; Eckhard Mühlbauer
Journal:  Int J Mol Sci       Date:  2013-03-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.